Biotechnology

Celltrion's SteQeyma autoinjector gets a CHMP nod, enhancing patient care and intensifying competition in Europe's crowded biosimilar market.

Bolstered by positive clinical data and top investors, Kalaris Therapeutics extends its runway to advance TH103, a next-gen treatment for neovascular AMD.

A Utah biotech reports promising results for a novel mRNA therapy that makes cancer cells look like measles, setting the stage for crucial animal trials.

Early Phase 1a data for Kalaris's new nAMD drug shows significant vision improvement and potential for extended durability, aiming to reduce patient burden.

Incyte's Minjuvi, a first-of-its-kind immunotherapy, gains EC approval for follicular lymphoma, offering patients a powerful new chemo-free option.

A key trial update de-risks Tenax Therapeutics' pivotal study for a novel heart failure therapy, boosting confidence in its path to market.

As biotech and pharma risks evolve, Verist Inc. launches tailored coverage, aiming to redefine insurance with a high-touch, data-driven service model.

A Phase 1 trial for Moleculin's WP1066 shows encouraging safety and anti-tumor activity for children with deadly brain tumors like DIPG.

NorthStar Medical Radioisotopes will showcase its revolutionary cancer-fighting isotopes, Ac-225 and Cu-67, at the prestigious J.P. Morgan conference.

CERo Therapeutics reports early safety success and dose escalation in its Phase 1 AML trial for CER-1236, a novel cell therapy for high-risk patients.

New data reveals a novel therapy shrinks tumors in salivary gland cancer, offering hope where few options exist and validating a new oncology platform.

Armed with breakthrough data on an AI-designed therapy that penetrates the brain, Rakovina Therapeutics heads to JPM Week to court major partners.

A new once-monthly, self-injected cholesterol drug gets FDA nod, offering more convenience and setting the stage for a major market push in China.

New data shows Vyriad's VV169 eliminated myeloma in mice without severe toxicity, signaling a potential shift to safer, scalable 'off-the-shelf' CAR T.

A new AI platform promises human-like chats for doctors, aiming to solve pharma's compliance and information overload challenges with on-demand science.

Zephyrus Innovations just got FDA clearance for VaporShield, a device protecting nurses from drug exposure. It’s a story of safety, market disruption, and efficiency.

Ayrmid and RoslinCT forge a key manufacturing pact for a new SAA therapy, revealing the critical infrastructure needed for resilient biotech returns.

A breakthrough clinical trial and a savvy financial move could net Fractyl Health $18M to advance its novel obesity treatment beyond the GLP-1 boom.

Biotech Immunome plans a massive stock offering. A deep dive into the high-stakes bet on its cancer pipeline and what it means for investors.

Kodiak Sciences is raising crucial capital with a stock offering, diluting investors but fueling its late-stage retinal drugs. Is this a necessary lifeline or a red flag?